• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

Bardoxolone (methyl)

(CAS: 218600-53-4)

Suppliers of Bardoxolone (methyl)

Company Name Email Tel Country
AbMole BioScience [email protected] 1-800-660-8580 USA

Fax: Purity: Brand:

AdooQ BioScience, LLC [email protected] 855-GO-ADOOQ (855-462-3667) (US & Canada Toll Free) 866-930-6790 (US & Canada Toll Free) +1-323-389-9269 (Outside of US & Canada) USA

Fax: 866-333-9607 (US & Canada Toll Free) +1-323-606-8156 (Outside of US & Canada)Purity: Brand:

Apexbio Technology LLC [email protected] +1-832-696-8203 USA

Fax: +1-832-641-3177Purity: Brand:

Ark Pharm, Inc. [email protected] +1 (847) 367-3680 USA

Fax: +1 (847) 367-3681Purity: Brand:

Astatech, Inc. [email protected] +1 (215) 785-3197 USA

Fax: +1 (215) 785-2656Purity: Brand:

BOC Sciences [email protected] 1-631-504-6093

Fax: 1-631-614-7828Purity: ≥ 98.0% Brand: BOC Sciences

Price and Availability: USD198/250mg (In stock)

BioVision, Inc., [email protected] 408-493-1800 Toll Free: 800-891-9699 (US Only) USA

Fax: 408-493-1801Purity: Brand:

Biochempartner Co., Ltd [email protected] 0086-13720134139; 0086-15971444841 China

Fax: Purity: 98% Brand: Biochempartner

CHEMSCENE, LLC [email protected] 732-484-9848 USA

Fax: 888-484-5008Purity: Brand:

Price and Availability: USD50/10mg () USD100/50mg ()

Cayman Chemical Company [email protected] Toll Free (USA and Canada Only): (800) 364-9897; Direct: (734) 971-3335;Technical Support Toll Free (USA and Canada Only): (888) 526-5351;Technical Support Direct: (734) 975-3888 USA

Fax: (734) 971-3640Purity: Brand:

MedChemexpress Co., Ltd. [email protected] 609-228-6898 USA

Fax: 609-228-5909Purity: Brand:

Price and Availability: USD50/10mg () USD100/50mg ()

MedKoo Biosciences, Inc. [email protected] 919-279-0682 USA

Fax: 919-980-4831Purity: Brand:

ProbeChem [email protected] 86-21-80183644

Fax: 86-21-68860190Purity: Brand:

Selleck Chemicals LLC [email protected] +1-832-582-8158 USA

Fax: +1-832-582-8590Purity: Brand:

Price and Availability: USD97/25mg (In stock) USD570/200mg (In stock)
Quality Control & MSDS Files: HPLC HPLC

Shanghai Haoyuan Chemexpress Co., Ltd. [email protected] +86 (21) 5187-0955 / +86 (21) 5895-5995 China

Fax: +86 (21) 5895-5996Purity: Brand:

Price and Availability: USD50/10mg () USD100/50mg ()

Target Molecule Corp. [email protected] (857) 239-0968 USA

Fax: 857-239-8801Purity: .98 Brand: TargetMol

Price and Availability: USD27/2mg () USD51/10mg () USD83/25mg () USD137/50mg () USD241/100mg ()

Inquiry Online

Salutation: *Country:
*Customer: *Company Name:
*Email: *Request quantity:

Notice: Your contact information will be sent to selected suppliers.

* Required Fields.

Background Information of Bardoxolone (methyl)

Bardoxolone methyl(RTA 401; NSC 713200) is the lead molecule in Reata's portfolio of Antioxidant Inflammation Modulators (AIMs).

Solubility of Bardoxolone (methyl)

Solubility Sources
DMSO MedChemexpress Co., Ltd.
(25°C) * In vitro DMSO 21 mg/mL (41.52 mM); Water<1 mg/mL (<1 mM); Ethanol<1 mg/mL (<1 mM); In vivo 4% DMSO+30% PEG 300+5% Tween+ddH2O5mg/mL Selleck Chemicals LLC

Storage Condition of Bardoxolone (methyl)

Storage Condition Sources

MSDS Information

MSDS Sources
MedChemexpress Co., Ltd.

Quality Control and Spectral Data

QC Reports Sources
[HNMR] [LCMS] [NP-HPLC] MedChemexpress Co., Ltd.
[HPLC] Selleck Chemicals LLC

Mechanism and Indications

Signaling Pathways NF-κB Autophagy
Target Keap1-Nrf2 Autophagy
Research Area Cancer
Indications End stage renal disease Diabetic nephropathy Non-insulin dependent diabetes

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
Bardoxolone (methyl) Reata Pharmaceuticals Inc End stage renal disease 2011/6/30 2013/10/31 Phase 3 Clinical
Bardoxolone (methyl) Reata Pharmaceuticals Inc Diabetic nephropathy 2009/4/30 2010/12/31 Phase 2 Clinical
Bardoxolone (methyl) Reata Pharmaceuticals Inc Diabetic nephropathy 2008/4/30 2009/6/06 Phase 2 Clinical
Bardoxolone (methyl) Reata Pharmaceuticals Inc End stage renal disease 2012/9/30 2013/10/31 Phase 2 Clinical
Bardoxolone (methyl) Reata Pharmaceuticals Inc Non-insulin dependent diabetes 2012/9/30 2013/10/31 Phase 2 Clinical
Bardoxolone (methyl) Reata Pharmaceuticals Inc End stage renal disease 2012/7/31 2013/10/31 Phase 2 Clinical
Bardoxolone (methyl) - Discontinued
Bardoxolone (methyl) - Phase 2

Chemical Information

M.Wt Formula CAS No. Synonyms
505.69 C32H43NO4 218600-53-4 NSC 713200; RTA 402; CDDO Methyl ester; (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-methyl 11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicene-4a-carboxylate

Structure Information of Bardoxolone (methyl)

Smiles O=C1C(C#N)=C[[email protected]@]2(C)[[email protected]](CC[[email protected]]([[email protected]@]3(C)[[email protected]@]4([H])[[email protected]@]5([H])[[email protected]@](CCC(C)(C)C5)(C(OC)=O)CC3)(C)C2=CC4=O)([H])C1(C)C
InChI InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1

Related Products

Other Form Products of Bardoxolone (methyl)

Name CAS Formula Suppliers
Bardoxolone 218600-44-3 C31H41NO4 17

Recommended Products in Same Target

Name CAS Formula Suppliers
CDDO-EA 932730-51-3 C33H46N2O3 8
RTA-408 1474034-05-3 C33H44F2N2O3 14
Isoalantolactone 470-17-7 C15H20O2 13
Gypenoside XVII 80321-69-3 C48H82O18 12
Nordihydroguaiaretic acid 500-38-9 C18H22O4 17
Curcumin 458-37-7 C21H20O6 26
Ezetimibe 163222-33-1 C24H21F2NO3 30
Dimethyl fumarate 624-49-7 C6H8O4 25
Bardoxolone 218600-44-3 C31H41NO4 17
Hinokitiol 499-44-5 C10H12O2 10
NK-252 1414963-82-8 C13H11N5O3 9
Ezetimibe D4 1093659-90-5 C24H17D4F2NO3 5
Danshensu 76822-21-4 C9H10O5 8
ML385 846557-71-9 C31H29N3O2S 8
Cpd16 C24H22N2O6S2 0
Cpd16-AA C28H26N2O10S2 0
TBE-31 936475-62-6 C21H18N2O2 1
AEM1 1030123-90-0 C20H14FN3O2S 5
Lyngbyabellin A 273202-85-0 C29H40Cl2N4O7S2 0
Grassypeptolide A 1010433-25-6 C56H79N9O10S2 0

Recommended Products in the Same Indication

Name CAS Formula Suppliers
Glibenclamide 10238-21-8 C23H28ClN3O5S 30
Mitiglinide (Calcium) 145525-41-3 C38H50CaN2O7 24
Bardoxolone 218600-44-3 C31H41NO4 17
Teneligliptin 760937-92-6 C22H30N6OS 12
Empagliflozin 864070-44-0 C23H27ClO7 22
MK 0893 870823-12-4 C32H27Cl2N3O4 10
Canagliflozin 842133-18-0 C24H25FO5S 24
Manidipine (dihydrochloride) 89226-75-5 C35H40Cl2N4O6 17
Teneligliptin (hydrobromide) 906093-29-6 C44H65Br5N12O2S2 13
Exendin-4 (Acetate) 914454-01-6 C186H286N50O62S 8
Trelagliptin 865759-25-7 C18H20FN5O2 18
Linagliptin 668270-12-0 C25H28N8O2 23
Saxagliptin 361442-04-8 C18H25N3O2 22
Cinacalcet (hydrochloride) 364782-34-3 C22H23ClF3N 15
Alogliptin 850649-61-5 C18H21N5O2 14
Alogliptin (Benzoate) 850649-62-6 C25H27N5O4 21
Aleglitazar (racemate) 475479-24-4 C24H23NO5S 6
Imeglimin (hydrochloride) 775351-61-6 C6H14ClN5 10
Imeglimin 775351-65-0 C6H13N5 10
Balaglitazone 199113-98-9 C20H17N3O4S 10

Chemical and Physical Properties

Appearance:yellow Solid Melting point:
Boiling point: Flash Point:
Water Solubility: Solubility:In vitro:DMSO,21 mg/mL(41.52 mM);In vitro:Water,Insoluble;In vitro:Ethanol,Insoluble;In vivo:Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):4% DMSO+30% PEG 300+5% Tween+ddH2OFor best results, use pro
Density: Merck:
BRN: Refractive Index:
Vapour: EINECS:
Optical Rotation: alpha:


[1].Prevention of prostate cancer with oleanane synthetic triterpenoid CDDO-Me in the TRAMP mouse model of prostate cancer By Gao, Xiaohua; Deeb, Dorrah; Liu, Yongbo; Arbab, Ali S.; Divine, George W.; Dulchavsky, Scott A.; Gautam, Subhash C.From Cancers (Basel). 2011; 3(3): 3353-3369
2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO), a synthetic analog of oleanolic acid, and its C28 methyl ester derivative (CDDO-Me), have shown potent antitumorigenic activity against a wide range of cancer cell lines, including prostate cancer cells in vitro, and inhibited the development of liver and lung cancer in vivo. In the present study, we examined the efficacy of CDDO-Me in preventing the development and progression of prostate cancer in the transgenic adenocarinoma of the mouse prostate (TRAMP) model. CDDO-Me inhibited the growth of murine TRAMPC-1 prostate cancer cells by inducing apoptosis through the inhibition of antiapoptotic p-Akt, p-mTOR and NF-κB. Early intervention with CDDO-Me (7.5 mg/kg) initiated at five weeks of age for 20 wk inhibited the progression of the preneoplastic lesions (low-grade PIN and high-grade-PIN) to adenocarcinoma in the dorsolateral prostate (DLP) and ventral prostate (VP) lobes of TRAMP mice. ...

[2].Reisman SA, Chertow GM, Hebbar S, Vaziri ND, Ward KW, Meyer CJ.Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney. J Am Soc Nephrol. 2012 Aug 2.
Inflammation and oxidative stress are hallmarks and mediators of the progression of CKD. Bardoxolone methyl, a potent activator of the nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated antioxidant and anti-inflammatory response, increases estimated GFR and decreases BUN, serum phosphorus, and uric acid concentrations in patients with moderate to severe CKD. However, it also increases albuminuria, which is associated with inflammation and disease progression. Therefore, we investigated whether this bardoxolone methyl-induced albuminuria may result from the downregulation of megalin, a protein involved in the tubular reabsorption of albumin and lipid-bound proteins. Administration of bardoxolone methyl to cynomolgus monkeys significantly decreased the protein expression of renal tubular megalin, which inversely correlated with the urine albumin-to-creatinine ratio. Moreover, daily oral administration of bardoxolone methyl to monkeys for 1 year did not lead to any adverse effects on renal histopathologic findings but did reduce serum creatinine and BUN, as observed in patients with CKD. Finally, the bardoxolone methyl-induced decrease in megalin corresponded with pharmacologic induction of renal Nrf2 targets, including NAD(P)H:quinone oxidoreductase 1 enzyme activity and glutathione content. This result indicates that Nrf2 may have a role in megalin regulation. In conclusion, these data suggest that the increase in albuminuria that accompanies bardoxolone methyl administration may result, at least in part, from reduced expression of megalin, which seems to occur without adverse effects and with strong induction of Nrf2 targets.

[3].McCullough PA, Ali S. Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl. Drug Des Devel Ther. 2012;6:141-9.
The intracellular and tissue balance of oxidant and antioxidant forces is a potential therapeutic target for a variety of agents in the treatment of complications due to chronic disease including diabetes mellitus and hypertension. There are a myriad of processes controlled at the level of genes, transcription factors, and protein messages that work to control the normal use of oxidative reactions within cells. Loss of control of these processes may lead to reversible dysfunction in many cell lines including the podocyte, renal tubular cells, and cardiac myocytes. Bardoxolone methyl is a novel nuclear regulator factor (Nrf-2) activator which works to tip the balance of effects towards antioxidation and as an observation made serendipitously, improves renal filtration function in humans after approximately 12 weeks of therapy. The improvement in estimated glomerular filtration can be up to 30% in those with stage 3 and 4 chronic kidney disease. However, experimental evidence suggests there may be a consequence of relative hyperfiltration in diseased kidneys as well as potential adverse effects on skeletal and cardiac myocytes. Only large, prospective randomized trials with carefully collected and adjudicated clinical outcomes will inform the research community on the therapeutic risks and benefits of this important new agent.

[4].Thomas M. A preliminary evaluation of bardoxolone methyl for the treatment of diabetic nephropathy. Expert Opin Drug Metab Toxicol. 2012 Aug;8(8):1015-22.
Introduction: The coordinated activation of Nrf-2-dependent signaling pathway is currently being investigated in a range of chronic diseases. Bardoxolone methyl is a potent, orally bioavailable Nrf-2 agonist. In a recent 52-week study, treatment with bardoxolone methyl improved renal function in patients with chronic kidney disease (CKD) and type 2 diabetes. This improvement was sustained for the duration of the treatment. Such agonists potentially offer new options for the complex management of renal impairment. Areas covered: A literature search was performed to analyze the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of bardoxolone methyl in both healthy volunteers and patients. Updated information about bardoxolone methyl, either after single administration or after chronic administration is also included. A special focus has been put on the putative mechanisms of action and potential toxicity profiles as well as an ongoing trials in patients with CKD and type 2 diabetes. Expert opinion: The development of an agent that leads to sustained improvement in renal function comes as a welcome relief to the millions of individuals with diabetes and CKD. However, much remains to be established regarding its actions in a complex and pleiotropic signalling cascade. Other triterpenoids with different PK/PD profiles are currently under development.

[5].Rojas-Rivera J, Ortiz A, Egido J. Antioxidants in kidney diseases: the impact of bardoxolone methyl. Int J Nephrol. 2012;2012:321714.
Drugs targeting the renin-angiotensin-aldosterone system (RAAS) are the mainstay of therapy to retard the progression of proteinuric chronic kidney disease (CKD) such as diabetic nephropathy. However, diabetic nephropathy is still the first cause of end-stage renal disease. New drugs targeted to the pathogenesis and mechanisms of progression of these diseases beyond RAAS inhibition are needed. There is solid experimental evidence of a key role of oxidative stress and its interrelation with inflammation on renal damage. However, randomized and well-powered trials on these agents in CKD are scarce. We now review the biological bases of oxidative stress and its role in kidney diseases, with focus on diabetic nephropathy, as well as the role of the Keap1-Nrf2 pathway and recent clinical trials targeting this pathway with bardoxolone methyl.

Tags: buy Bardoxolone (methyl) | Bardoxolone (methyl) IC50 | Bardoxolone (methyl) price | Bardoxolone (methyl) cost | Bardoxolone (methyl) solubility | Bardoxolone (methyl) purchase | Bardoxolone (methyl) manufacturer | Bardoxolone (methyl) research buy | Bardoxolone (methyl) order | Bardoxolone (methyl) MSDS | Bardoxolone (methyl) chemical structure | Bardoxolone (methyl) Storage condition | Bardoxolone (methyl) molecular weight | Bardoxolone (methyl) mw | Bardoxolone (methyl) datasheet | Bardoxolone (methyl) supplier | Bardoxolone (methyl) cell line | Bardoxolone (methyl) NMR | Bardoxolone (methyl) MS | Bardoxolone (methyl) IR | Bardoxolone (methyl) solubility | Bardoxolone (methyl) Safe information | Bardoxolone (methyl) Qc and Spectral Information | Bardoxolone (methyl) Clinical Information | Bardoxolone (methyl) Clinical Trial | Bardoxolone (methyl) Route of Synthesis | Bardoxolone (methyl) storage condition | Bardoxolone (methyl) diseases and conditions | Bardoxolone (methyl) flash point | Bardoxolone (methyl) boiling point | Bardoxolone (methyl) melting point | Bardoxolone (methyl) storage condition | Bardoxolone (methyl) brand